Partnership to develop and manufacture biosimilars

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture.

The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.

Jonathan Goldman, CEO of Abzena, said: “This new integrated offering will provide our partners a de-risked approach to biosimilar development, all the way to clinical development and ultimately to the market.”

Gerrit Hagens, Director at BioXpress Therapeutics, commented: “This partnership allows for a simplification of drug development timelines for the biosimilars market. The BioXpress Therapeutics and Abzena strengths are complementary and this partnership provides a flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free